Company / FCF Margin
Beam Therapeutics Inc. FCF Margin History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-257.6%
FY2025
5-year range
-560.8% / -43.4%
FY2021-FY2025
Trend
+54.1%
vs FY2024
Sector context
#102 of 134
Health Care
What the data says
Beam Therapeutics Inc.'s fcf margin of -257.6% is lower than 76% of companies in the Health Care sector (FY2025). FCF Margin returned to growth in FY2025 after 2 years of decline, reaching -257.6%.
Based on SEC 10-K filings.
-257.6% in FY2025 with a 5-year CAGR of +469303.5%.
Declined from -48.4% to -257.6% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -214.3pp
- 5-Year Change
- +469303.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 134This company -257.6% Sector average -637.8%
▼
+59.6% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 54.1% year-over-year.
- Currently 380.1pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -257.6% | +54.1% |
| FY2024 | -560.8% | -1057.9% |
| FY2023 | -48.4% | -11.7% |
| FY2022 | -43.4% | +80.1% |
| FY2021 | -218.1% | +100.0% |
| FY2020 | -469561.1% | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026